Ken Fisher Incyte Corp Transaction History

Fisher Asset Management, LLC

$229 Billion
Q2 2024

A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Incyte Corp stock. As of the latest transaction made, Fisher Asset Management, LLC holds 9,258 shares of INCY stock, worth $630,099. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,258

Previous 9,092 1.83%

Holding current value

$630,099

Previous $517,000 8.51%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$51.18 - $63.75 $8,495 - $10,582	166 Added 1.83%	9,258 $561,000
Q1 2024 May 09, 2024	SELL	$56.55 - $66.59 $2 Million - $2.35 Million	-35,299 Reduced 79.52%	9,092 $517,000
Q4 2023 Mar 05, 2024	BUY	$52.16 - $64.19 $11,579 - $14,250	222 Added 0.5%	44,391 $2.79 Million
Q4 2023 Feb 06, 2024	BUY	$52.16 - $64.19 $9,753 - $12,003	187 Added 0.43%	44,169 $2.77 Million
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $31,773 - $36,261	550 Added 1.27%	43,982 $2.54 Million
Q2 2023 Dec 12, 2023	SELL	$60.95 - $75.51 $33,522 - $41,530	-550 Reduced 1.25%	43,432 $2.7 Million
Q2 2023 Aug 08, 2023	SELL	$60.95 - $75.51 $9,934 - $12,308	-163 Reduced 0.37%	43,432 $2.7 Million
Q1 2023 Dec 12, 2023	SELL	$70.23 - $86.01 $48,177 - $59,002	-686 Reduced 1.56%	43,296 $3.13 Million
Q1 2023 May 01, 2023	BUY	$70.23 - $86.01 $1,474 - $1,806	21 Added 0.05%	43,595 $3.15 Million
Q4 2022 Feb 03, 2023	BUY	$67.18 - $84.11 $499,886 - $625,862	7,441 Added 20.59%	43,574 $3.5 Million
Q3 2022 Nov 08, 2022	SELL	$66.18 - $82.86 $326,664 - $408,996	-4,936 Reduced 12.02%	36,133 $2.41 Million
Q2 2022 Aug 09, 2022	BUY	$66.18 - $83.18 $299,001 - $375,807	4,518 Added 12.36%	41,069 $3.12 Million
Q1 2022 May 05, 2022	SELL	$66.02 - $79.71 $182,545 - $220,398	-2,765 Reduced 7.03%	36,551 $2.9 Million
Q4 2021 Feb 02, 2022	BUY	$63.34 - $74.11 $28,756 - $33,645	454 Added 1.17%	39,316 $2.89 Million
Q3 2021 Oct 26, 2021	BUY	$68.67 - $84.02 $238,696 - $292,053	3,476 Added 9.82%	38,862 $2.67 Million
Q2 2021 Jul 27, 2021	BUY	$79.87 - $87.53 $48,401 - $53,043	606 Added 1.74%	35,386 $2.98 Million
Q1 2021 Apr 27, 2021	SELL	$76.02 - $100.5 $186,933 - $247,129	-2,459 Reduced 6.6%	34,780 $2.83 Million
Q4 2020 Jan 29, 2021	SELL	$80.74 - $97.7 $62,734 - $75,912	-777 Reduced 2.04%	37,239 $3.24 Million
Q3 2020 Nov 10, 2020	SELL	$85.07 - $109.69 $266,269 - $343,329	-3,130 Reduced 7.61%	38,016 $3.41 Million
Q2 2020 Aug 07, 2020	SELL	$74.18 - $108.93 $667 - $980	-9 Reduced 0.02%	41,146 $4.28 Million
Q1 2020 Apr 28, 2020	SELL	$63.18 - $85.97 $305,728 - $416,008	-4,839 Reduced 10.52%	41,155 $3.01 Million
Q4 2019 Feb 12, 2020	BUY	$73.04 - $95.72 $1.26 Million - $1.66 Million	17,304 Added 60.31%	45,994 $4.02 Million
Q3 2019 Oct 29, 2019	BUY	$72.82 - $86.52 $35,900 - $42,654	493 Added 1.75%	28,690 $2.13 Million
Q2 2019 Jul 30, 2019	SELL	$73.52 - $88.7 $27,275 - $32,907	-371 Reduced 1.3%	28,197 $2.4 Million
Q1 2019 Apr 22, 2019	BUY	$63.56 - $88.17 $219,917 - $305,068	3,460 Added 13.78%	28,568 $2.46 Million
Q4 2018 Jan 25, 2019	BUY	$58.5 - $69.94 $1.11 Million - $1.32 Million	18,925 Added 306.08%	25,108 $1.6 Million
Q3 2018 Oct 24, 2018	SELL	$61.75 - $74.23 $58,045 - $69,776	-940 Reduced 13.2%	6,183 $427,000
Q2 2018 Jul 09, 2018	BUY	$60.85 - $83.98 $62,006 - $85,575	1,019 Added 16.69%	7,123 $477,000
Q1 2018 May 11, 2018	SELL	$83.06 - $100.98 $809,004 - $983,545	-9,740 Reduced 61.47%	6,104 $509,000
Q1 2018 Apr 19, 2018	BUY	$83.06 - $100.98 $180,489 - $219,429	2,173 Added 15.89%	15,844 $1.32 Million
Q4 2017 Jan 24, 2018	SELL	$93.56 - $116.6 $32,839 - $40,926	-351 Reduced 2.5%	13,671 $1.3 Million
Q3 2017 Oct 17, 2017	BUY	$109.15 - $138.27 $1.53 Million - $1.94 Million	14,022	14,022 $1.64 Million

Others Institutions Holding INCY

# of Institutions

629

Shares Held

198M

Call Options Held

766K

Put Options Held

476K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track Ken Fisher's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Account